Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks.
The therapeutic response to phenelzine sulfate was evaluated during 6 months' treatment of 35 outpatients meeting DSM-III criteria for panic disorder or agoraphobia with panic attacks. The possible influence of nonspecific predictors of drug efficacy and some biochemical parameters were investigated. Therapeutic response was assessed on standardized rating scales. Agoraphobic patients showed a significantly higher frequency of panic attacks when compared to the subjects with uncomplicated panic disorder. Phenelzine treatment blocked panic attacks in 100% of the patients with panic disorder and in 94.7% of the agoraphobics. Anticipatory anxiety and avoidant behavior improved markedly, although not statistically significantly, in 73.6% of the agoraphobics.
D000293:Adolescent; D000328:Adult; D000379:Agoraphobia / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005239:Fear; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010200:Panic; D010555:Personality Inventory; D010624:Phenelzine / Q000008:administration & dosage / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales
D010624:Phenelzine